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Abstract
Worldwide efforts to eradicate polio caused a tipping point in polio vaccination strategies. A switch from the oral polio
vaccine, which can cause circulating and virulent vaccine derived polioviruses, to inactivated polio vaccines (IPV) is
scheduled. Moreover, a manufacturing process, using attenuated virus strains instead of wild-type polioviruses, is
demanded to enhance worldwide production of IPV, especially in low- and middle income countries. Therefore,
development of an IPV from attenuated (Sabin) poliovirus strains (sIPV) was pursued. Starting from the current IPV
production process based on wild type Salk strains, adaptations, such as lower virus cultivation temperature, were
implemented. sIPV was produced at industrial scale followed by formulation of both plain and aluminium adjuvanted
sIPV. The final products met the quality criteria, were immunogenic in rats, showed no toxicity in rabbits and could be
released for testing in the clinic. Concluding, sIPV was developed to manufacturing scale. The technology can be
transferred worldwide to support post polio-eradication biosafety goals.
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Introduction
Vaccines that provide protection against poliomyelitis have
been available for decades [1]. Yet large efforts are undertaken
in WHO’s global polio eradication initiative (GPEI) to obtain the
next generation vaccines that are safe and available at low
costs [2]. These vaccines are needed both for the ‘endgame’ in
polio eradication and after eradication to prevent the risk of a
global outbreak due to accidental or deliberate re-introduction
of the virus. One of the anticipated next generation vaccines is
an inactivated polio vaccine (IPV) based on the attenuated
Sabin poliovirus strains resulting in a so-called Sabin-IPV
(sIPV) [3]. The Sabin polioviruses (PV) are currently used in
live oral polio vaccines (OPV) [4] and will provide additional
bio-safety, over the wild-type viruses, during the manufacturing
process [5]. Bio-safety requirements are becoming more
stringent as new containment guidelines are drafted by the
WHO’s Global Action Plan for Wild Poliovirus Laboratory
Containment III (GAPIII) [6]. Future production and quality
control of IPV using wild-type strains will require at least
biosafety level 3 facilities [7]. This will not only increase
manufacturing costs but will also limit the possibility of IPV
manufacturing in low- and middle income countries for instance
due to requirements on immunization coverage. The use of
alternative strains like Sabin PV would require less stringent
biocontainment, is encouraged by the WHO [5] and allows
manufacturing in low- and middle income countries, which
potentially lowers manufacturing costs [8]. Moreover, the use of
an IPV instead of OPV will prevent the emergence of
circulating vaccine-derived PV (cVDPVs), which may
potentially re-seed the world with PV and negate the GPEI
accomplishments [9].
The development of the currently used IPV production
process (for a process overview see Figure 1) dates back to
the 1960s when at the RIV in Bilthoven a process was
developed based on micro-carrier technology and primary
monkey kidney cells [10,11]. This process was scaled-up to
350-L and later 750-L bioreactors. Additionally, the Vero cell
line was introduced to replace the then used tertiary monkey
kidney cells. To support manufacturing and increase the
knowledge on IPV manufacturing, efforts like multivariate data
analysis and the development of scale-down models, i.e. lab-
scale equivalents of the manufacturing-scale processes, have
been undertaken [12,13]. The availability of scale-down
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models, unique in the vaccine world, allows rapid assessment
of process changes.
Based on our vast history in IPV development and
production [11], our previous experience with sIPV [14] and
technology transfer [15-17] a project for the development and
technology transfer of sIPV manufacturing under supervision of
the WHO was initiated. Initially a proof-of-principle study was
performed. In this study, sIPV was prepared from OPV as virus
source. The three PV sub-types, obtained separately (Bio
Farma, Indonesia), were concentrated, purified and inactivated
and shown to yield a sIPV that was immunogenic in an animal
model [3]. In principle, OPV manufacturers could, by acquiring
correct downstream processing (DSP) equipment, produce
sIPV. However, larger quantities of virus harvest (100-800 fold
of current production quantities) are needed and upstream
processing (USP) should be scaled-up [18].
Here we report the results of limited (to be able to quickly
show proof of concept) process development for sIPV based
on the established IPV production process, the subsequent
manufacturing of clinical lots, their stability and pre-clinical
studies. This work resulted in a vaccine that has recently been
tested in the clinic (phase I/IIa) [19,20].
Methods
Ethics statements regarding animal studies
The abnormal toxicity study in suckling mice and guinea pigs
and immunogenicity tests in rats used in this study were
agreed upon by the Committee on Animal Experimentation of
the Netherlands Vaccine Institute (Bilthoven, the Netherlands)
(Study Permit numbers AAP 201000262, 201000302,
201000303, 2010000304, 2010000305, 2010000306,
2010000307, 201000310, 201100030, 201100054, 201100056,
201100101, 201100151, 201100170, 201100195, 201100214,
201100289, 201100345, 201200137, 201200154, 201200227
and 201200262). Animal handling in this study was carried out
in accordance with relevant Dutch national legislation, including
the 1997 Dutch Act on Animal Experimentation.
The protocol for the toxicity study in rabbits was reviewed
and approved by the Animal Welfare Officer and Ethical
Committee of WIL Research Europe B.V. (former name:
Figure 1.  Process overview for preparation of trivalent IPV.  Monovalent bulks are prepared for each PV (type 1, 2 and 3)
separately. During monovalent bulk preparation Vero cells are expanded using two pre-culture steps and a cell culture followed by
virus culture. Virus is purified using normal flow filtration for clarification, tangential flow filtration for concentration and two
chromatography units, size exclusion and ion exchange chromatography. Purified virus is subsequently inactivated using
formaldehyde. Subsequently these are mixed to obtain trivalent bulk prior to formulation and filling.
doi: 10.1371/journal.pone.0083374.g001
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NOTOX B.V.) as required by the Dutch Act on Animal
Experimentation (Study Permit Numbers: DEC 08-48 and
10-18). The OECD guidance document on humane endpoints
(ENV/JM/MONO/ 2000/7) is applicable for all animal studies
carried out at WIL Research Europe B.V.. No distress or
discomfort was noted during this study.
Lab scale experiments
Upstream processing.  Vero cells obtained from WHO
(10-87) originally derived from ATCC (CCL-81) were used as
host for PV production. Sabin PV type 1 (LSc 2ab KP2), Sabin
PV type 2 (P712 Ch2ab-KP2) and Sabin PV type 3 (Lot 457-III-
Pfizer) were used.
Studies on virus culture conditions were carried out in 5-L
glass bioreactors (Sartorius Stedim Biotech). Cell cultures were
done in EMEM supplemented with bovine serum (BS) and 3 g
L-1 micro-carriers (Cytodex 1; GE Healthcare) with the following
settings: T of 37°C, pH of 7.2 and DO (dissolved oxygen) of
50% by headspace aeration. Glucose was added daily when
the concentration was below 5 mM. Prior to virus culture the
media was exchanged to M199. Virus cultures conditions were:
T of 32.5 or 33.5°C, pH of 7.4, DO of 25% by headspace
aeration.
Downstream processing.  Virus was harvested, clarified,
concentrated, purified, first on size using size exclusion
chromatography (SEC) and second by ion exchange
chromatography (IEX), and finally inactivated as described
previously [13].
Analytics.  Cell counts were determined using a
Nucleocounter (Chemometec). Glucose concentration was
determined using a Bioprofile 100 plus (Nova Biomedical, MA).
Cytopathic effects (CPE) were monitored microscopically. Virus
was quantified by titer measurements (CCID50) [21] and by a
modified D-antigen ELISA [22] for in-process samples.
Clinical lots manufacturing
Cell and virus culture.  Vero cells from a manufacturers
working cell bank were used. Master and working seedlots
were prepared from Sabin type 1 LSc 2ab KP2 (WHO/
Beringwerke SO+1, 1976), type 2 P712 Ch2ab-KP2 (WHO/
Behringwerke SO+1, 1976) and type 3 (Pfizer RSO1, SO+5, lot
457-III, 1963; supplied by Institute Mérieux to RIVM in 1991)
[23]. Working seedlots were additionally tested for
neurovirulence in monkeys (Bio Farma, Indonesia) [24] and
analyzed with MAPREC (mutant analysis by PCR and
restriction enzyme cleavage; NIBSC/HPA, UK) [25] and RCT40
(replicating properties 36°C- 40°C; AFSSAPS, France) [24] to
assess genetic stability with respect to biosafety (Table 1).
Cell and virus culture was carried out in two 350-L (working
volume) bioreactors. In short, thawed Vero cells were used to
directly inoculate a 15-L fed-batch pre-culture (EMEM
supplemented with BS and Cytodex 1 microcarriers) [26]. After
trypsinization [26]; a 2nd pre-culture using the recirculation
culture method [27] was done to have sufficient cell to inoculate
two 350-L bioreactors at 0.1 × 106 cells mL-1. After medium
exchange [28], virus culture was started (M199; Multiplicity of
infection (MOI)=0.01; T=32.5°C).
Purification.  Virus from the two 350-L (working volume)
bioreactors was harvested via a sieve (mesh 75 µm) to obtain a
virus harvest free of micro-carriers [13]. Clarification was done
using normal flow filtration with a Millipore POD-holder
containing C0HC depth filters followed by an Express SHC
0.45/0.22 µm combination filter (Millipore) [3,13] .
Concentration was done by tangential flow filtration using 100
kDa filters [13]. Purification was done by size exclusion
chromatography (Sepharose CL-6B (GE Healthcare) [11,29];
elution buffer 20mM phosphate buffer pH 7.0) and ion
exchange chromatography (DEAE-Sephadex A50 (GE
Healthcare) [11,30]; elution buffer 20mM phosphate buffer
pH7.0).
Inactivation.  Purified virus was stabilized with concentrated
M199 containing glycine (final conc. 5g L-1). Inactivation was
done following the standard method: 0.025% formaldehyde
incubation for 13 days at 37°C. An intermediate filtration (0.22
µm) was performed at day 6-8 [5]. The resulting monovalent
bulk was stored at 2-8°C.
Preparation of trivalent vaccine.  Monovalent bulks of PV
type 1, 2 and 3 were mixed to a ratio of 60:96:192 D-antigen
prior to sterile filtration. The sIPV final bulk was subsequently
prepared by addition (via 0.22 µm filter) of the mixed trivalent
bulk and dilution buffer containing phosphate, phenoxyethanol
and formaldehyde. Aluminium hydroxide adjuvanted sIPV final
bulk was prepared as described above with the inclusion of the
addition of sterile Alhydrogel (Brenntag) (directly) to the final
bulk. Final bulks were mixed for 10 minutes prior to setting the
Table 1. Biosafety and viral safety testing of Sabin PV master (MS) and working (WS) seedlots.
Seedlot Virus titer (Log10 CCID50 mL-1) Monkey Neurovirulence1 MAPREC2 RCT401 Extraneous agents/Viral safety3
MS PV type 1 8.85 Not determined Conform Conform Conform
MS PV type 2 7.52 Not determined Conform Conform Conform
MS PV type 3 8.23 Not determined Conform Conform Conform
WS PV type 1 8.90 Conform Conform Conform Conform
WS PV type 2 7.55 Conform Conform Conform Conform
WS PV type 3 8.45 Conform Conform Conform Conform
1 Reproductive Capacity at 40°C Temperature (RCT40) and Monkey Neurovirulence: Tests and requirements according to WHO recommendations for OPV [24]. 2 Mutant
Analysis by PCR and Restriction Enzyme Cleavage (MAPREC): Test and requirements according to new WHO recommendations for OPV [25]. 3 Test and requirements
according to the European Pharmacopoeia [31,43].
doi: 10.1371/journal.pone.0083374.t001
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pH. The final lots were prepared by filling the final bulk in
aliquots of 0.6-0.7g in 3 mL sterile siliconized vials using a
Bausch & Ströbel ksf 1027 machine.
Analytics.  During the process, sampling was done, as
required for release of sIPV final lots. In Table 2 a list of the
most relevant assays for release is given. A qualified QC
department carried out these assays.
Cell counts were performed using a hemocytometer.
Cythopathic effects (CPE) were monitored microscopically.
Virus was quantified by titer measurements (CCID50) and D-
antigen ELISA [14] for release. SDS-PAGE was done using
Table 2. Release requirements1 of plain and adjuvanted sIPV.
Cell culture  
Identity Vero cells
Mycoplasma Absent
Extraneous viruses Absent
Virus harvest  
Sterility Absence of growth (Tryptic Soy Broth & Thioglycollate broth)
Mycoplasma Absent
Extraneous viruses Absent
Purified virus  
Purity (ratio total protein and D-antigen) ≤0.1 µg DU-1
Sterility As above
Identity PV type 1, 2 OR 3
Residual host cell proteins Consistent clearance
Monovalent Bulk  
Inactivation kinetics PV titer below detection limit after 120h
Formaldehyde >2 mM
Sterility As above
PV identity Contains PV type 1, 2 OR 3
Inactivation Full absence of active PV after 10 and 13 days
D-antigen content Information for calculation
Trivalent bulk  
Inactivation Full absence of active PV in 1,500 calculated human doses
Sterility As above
D-antigen content Information for calculation
Final bulk Plain Adjuvanted
pH 6.8-7.4 6.8-7.4
Phenoxyethanol 31-42 mM 31-42 mM
Formaldehyde 2 0.7-2.4 mM 0.7-1.3 mM
Sterility As above As above
D-antigen content ≥75% nominal value ≥75% nominal value
Final lot Plain Adjuvanted
Appearance Bright red-orange fluid Turbid red-orange fluid
PV identity Contains type PV 1, 2 and 3 Contains type PV 1, 2 and 3
D-antigen content ≥75% nominal value ≥75% nominal value
Residual host cell DNA 3 ≤100 pg shd-1 ≤100 pg shd-1
Bovin Serum Albumin 3 ≤50 ng shd-1 ≤50 ng shd-1
Total protein ≤20 µg mL-1 ≤20 µg mL-1
Endotoxin ≤10 IU mL-1 ≤10 IU mL-1
Extractable volume ≥0.5 mL ≥0.5 mL
pH 6.8-7.4 6.8-7.4
Sterility As above As above
Free D-antigen Not applicable < 1%
Aluminium Not applicable 0.26-0.36 mg mL-1
Abnormal toxicity (in mice and guinea pigs) No illness No illness
1 Most important release tests drafted for the production of the phase I clinical lots are given. It should be noted that the release criteria could change due to further product
development. 2 Formaldehyde requirement is dependent on the amount of monovalent bulk used to prepare the final bulk. 3 Test is performed at an earlier stage in view of
the lower detection limit.
doi: 10.1371/journal.pone.0083374.t002
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precast 4-20% gradient gel (Pierce) with Tris-HEPES buffer
(Pierce). Vero host cell protein concentrations were determined
using a Vero Cell HCP ELISA kit F500 according to the
manufacturer’s instructions (Cygnus Technologies, NC).
MAPREC and RCT40 were performed as described in WHO
guidelines [24,25].
Preclinical studies - Rat immunogenicity.  The rat
immunogenicity was determined essentially as described
previously [31,32]. In short, TOX rats (weighing 175-250g) that
were screened for the absence of PV antibodies were injected
intramuscularly with 0.5 mL of prepared vaccine dilutions
(group size 10 per dilution). Blood samples were taken 21 days
after injection. Collected sera (stored at -20°C until use) were
analyzed for neutralizing antibodies. Serial dilutions (with
M199) of heat inactivated sera (30 min 56°C) were prepared in
a 96-wells plate and incubated with 50 µl (2 × 103 TCID50 mL-1)
PV type 1 Mahoney, PV type 2 MEF-1, or PV type 3 Saukett for
3h at 35-37°C in a CO2 incubator and subsequently stored
overnight at 2-8°C. After addition of Vero cells (50 µL at 2 × 105
cells mL-1) the 96-wells plates were incubated for 7 days at
35-37°C. Supernatants were discarded and cells were stained
with a crystal violet solution containing 5% formaldehyde.
Presence of full monolayers of Vero cells indicated a complete
neutralization of the virus. The neutralization antibody score
represents the highest dilution (log2; with a test maximum of
12) where complete neutralization was observed. For
comparison of sIPV with conventional IPV, the international
standard PU91-01 was diluted towards the conventional IPV
dose (40/8/32 DU/shd).
Preclinical studies - Toxicity study in rabbits.  A repeated
dose and local tolerance toxicity study followed by a two week
recovery period was carried out in rabbits (NOTOX, the
Netherlands) according to EMA guidelines [33]. In short, New
Zealand white rabbits (group size of 16, equally distributed
among sexes) were treated by intramuscular injection with 0.5
mL vaccine or placebo (vaccine without D-antigen) at day 1,
15, 29, 43 and 57). Animals were necropsied at day 60 (n=10)
or day 71 (n=6). The following observations and examinations
were evaluated: clinical signs (daily), skin irritation (24 and 48
hours after each administration), body weight (weekly), food
consumption (twice weekly), ophthalmoscopic examination
(during pretest, end of treatment and end of recovery), rectal
body temperature (during pretest, prior to each dosing and
approximately 2 hours after dosing), clinical pathology (Pretest,
Days 4, 57, 60 and 71), macroscopy at termination and organ
weights and histopathology on a selection of tissues.
Statistical analysis
Two sided Student t-tests were performed with α=0.05.
Numbers are given as means with standard deviations.
To determine the regression line slopes, no weighted
regression was used. This was chosen based on the use of
medians when concerning animal tests in contrast to the use of
the means. In addition, the observed standard deviation from
the median did not increase with increasing values. The
significance (95% confidence) of the slopes was tested using
an extra sum of squares F-test with the null hypothesis being a
horizontal line (i.e. slope=0) (Graphad Prism 6 for Windows).
Results
Drafting product and process specifications
The specifications (Table 2) for the release and control of
sIPV and aluminium hydroxide adjuvanted sIPV were drafted
based on WHO [5] and EP monograph [31] for IPV
manufacturing. Some product requirements, like formaldehyde
content and pH, were based on the available IPV experience.
Requirements related to the adjuvation with aluminium
hydroxide were set after initial research [34]. The WHO OPV
guidelines [24] were taken into account to assess the Sabin PV
genetic stability with respect to biosafety, i.e. temperature
sensitivity and revertants.
Process development prior to manufacturing of clinical
lots
In view of the relatively short timelines in the polio
eradication program it was chosen to prepare a sIPV with
limited process development time prior to production of clinical
lots. Process development therefore focused on Sabin strain
specific adaptations like MOI and virus cultivation temperature
and chromatography (discussed below). In addition, a
disposable clarification unit was introduced to replace the
Celite cake for depth-filtration. On all other aspects the
production process was similar to conventional IPV
manufacturing.
Selection of MOI and virus cultivation temperature.  In
OPV manufacturing, the virus cultivation temperature for Sabin
PV is lower (at a maximum of 35°C [24]) than the temperature
used for wild-type PV in conventional IPV manufacturing
(36-37°C) [18,35]. This lower temperature is required to ensure
the temperature sensitivity of the Sabin PV and minimize
revertants to ensure a safe OPV. Although here an inactivated
product has been developed, manufacturing itself should be
biosafe and one of the prerequisites was to ensure the safety
of the prepared virus harvest with respect to revertants of
Sabin PV.
The effects of virus culture temperature and multiplicity of
infection (MOI) on the virus culture yields and culture time were
assessed using PV type 2. No differences in virus yields were
observed when the MOI was decreased from 0.1 to 0.01.
Decreasing the temperature from 33.5°C to 32.5°C, had a
negative effect on virus yields. Virus titers were 7.7 ± 0.1 (n=3)
and 7.2 ± 0.1 (n=3) Log10 CCID50 mL-1 for cultures at
respectively 33.5°C and 32.5°C. D-antigen (a measure for
immunogenic virus) concentrations were 25 ± 3 (at 33.5°C) and
11 ± 5 DU mL-1 (at 32.5°C). Under all tested conditions virus
culture was complete within 4 days, i.e. cytopathic effect (CPE)
>90% and both virus titers and D-antigen (a measure for
immunogenic virus) concentrations remained constant. Despite
the lower yields at 32.5°C, this cultivation temperature was
selected for preparing the virus seeds and clinical trial material.
This choice was made to minimize the risk of PV revertants.
Since no difference was observed when using a lower MOI, an
MOI of 0.01 was used as it is preferred since smaller amounts
of virus working seedlots will be needed.
Chromatography resin selection and buffer
strength.  Initial process development was done to confirm the
Next Generation IPV Manufacturing
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use of resins and procedures available for wild-type PV. The
present SEC resin and procedure were applicable for use with
Sabin PV (data not shown). For IEX a choice between two
validated resins needed to be made. Both DEAE Sephadex
A-50 [30] and DEAE Sepharose Fast Flow [13] have been used
for purification of PV. In both cases impurities are captured
while Salk PV flows through. Initial studies using Sabin PV
Type 1 showed some non-specific binding of the PV to DEAE
Sepharose Fast Flow; this was confirmed for Sabin PV Type 2.
The alternative resin DEAE Sephadex A50 allowed efficient
separation of Sabin PV type 1, 2 and 3.
During the proof of principle study [23] in which OPV bulks
were obtained to generate IPV, a precipitate was noticed
during inactivation. Analysis showed that this precipitate was a
phosphate based precipitate without product. The main source
of the phosphate was traced back to the purification process
where a 40mM phosphate buffer was used during
chromatography (both SEC and IEX). Application of a weaker
phosphate buffer (20mM) and the impact on product elution
and inactivation was assessed. Product elution profiles in SEC
and IEX using a 20mM phosphate buffer were comparable with
those obtained after eluting with a 40mM phosphate buffer.
Inactivation of virus eluted with 20mM phosphate was
comparable while precipitates were absent.
Manufacturing of clinical lots
Preparation of virus seed.  Sabin PV strains closest to the
Sabin original strains (PV T1: SO+1 Behringwerke 1976; PV
T2: SO+1 Behringwerke 1976; and PV T3: RSO+1 Pfizer 1963)
were used to produce new virus master seedlots at 10-L scale.
The virus working seedlots were produced at 350-L scale [3].
These seeds were tested for neurovirulence using the monkey
neurovirulence test [24]. However, due to limited global test
capacity and to minimize costs it was chosen to only test the
working seedlots. It was argued that the working seeds
represent, on a worst case base, the quality of the master seed
with respect to neurovirulence. Next to passing the
neurovirulence test, the master and working seedlots also
passed the tests for extraneous agents, RCT40 (reproductive
capacity at 40°C temperature) and MAPREC (Mutant Analysis
by PCR and Restriction Enzyme Cleavage ) (Table 1).
Upstream processing.  The preparation of sIPV was done
in a physically separated production area in the established
cGMP facilities for conventional IPV manufacturing. For each
virus type two monovalent bulks were prepared. Vero cell
culture was carried out in twin 350-L bioreactors [12]. In Figure
2A, the average growth curve of the 12 cultures (6 bulks in twin
bioreactors) at 350-L scale is given. Cell culture was started at
an inoculation density of 0.1 × 106 cells mL-1. Cells grew
adherent to micro-carriers (average growth rate 0.025 h-1) to
reach 1.1 × 106 cells mL-1 after 4 days when the micro-carriers
were covered by a confluent layer of cells. At this point, the
bovine serum containing medium was exchanged with serum
free virus culture media. Subsequently, cells were infected with
Sabin PV. Virus culture proceeded comparably and was
independent of the virus type used for infection. Cell lysis was
complete after 4-5 days as was determined based on the CPE
observed microscopically (Figure 2B). Virus yields were based
on virus titers (Figure 2C) and D-antigen (Figure 2D). While
comparable virus titers were observed for the production of
Sabin PV type 1 and 3, the yields for Sabin PV type 2 were
significantly lower (2-tailed t-test; α=0.05 p=0.0043). D-antigen
yields are not comparable between virus types as they are type
(and antibody) specific [36]. From Figure 2C&D it was
concluded that virus cultures were reproducible. The virus
harvests were negative for revertants of Sabin PV as analyzed
by RCT40 and MAPREC.
Downstream processing.  Virus from the twin bioreactors
was harvested and pooled prior to purification. Harvested virus
was first clarified using normal flow filtration (NFF), which
resulted in a decrease in fluid turbidity from 54 ± 6 NTU
(Nephelometric Turbidity Unit) to 0.4 ± 0.4 NTU (n=5;
determined mid-processing). The clarified virus was
subsequently concentrated from approx. 700L to 1L using
tangential flow filtration (TFF). Product recoveries, based on D-
antigen units (DU), during the filtration steps were 90% ± 3%
and 68% ± 11% for respectively NFF and TFF (Table 3).
The concentrated product was purified using 2-step
chromatography starting with SEC. In Figure 3A a typical SEC
elution pattern for Sabin PV is given. The 1st peak contains
mostly large cell components. PV is found in the 2nd peak as is
illustrated by SDS-PAGE (Figure 3B) where the presence of
the viral proteins is more pronounced when purification with
SEC was done. An average D-antigen recovery of 68% ± 11%
was found for SEC (Table 3).
Subsequently the negatively charged molecules, like nucleic
acids and proteins, were removed using IEX chromatography.
PV should not interact with the matrix as was the case for
Sabin PV type 1 and 3, where a plug flow was observed
(Figure 3C). However, Sabin PV type 2 showed some
interaction with the matrix as is apparent from the
chromatogram (Figure 3C). The presence of the plug flow type
chromatogram for Sabin PV type 1 and 3 allowed collection of
the PV after IEX without major losses. Sabin PV type 1 and 3
were collected with 99.5% D-antigen recovery (Table 3).
Relatively high losses (72%) were observed during IEX for
Sabin PV type 2 (Table 3). The efficiency of the purification is
illustrated by the SDS-PAGE in Figure 3B. After IEX the viral
proteins are clearly purified from the other protein present after
SEC. Removal of impurities was also shown for Vero host cell
proteins and host cell DNA (Figure 3D). After IEX host cell
protein concentrations were below 0.3 µg mL-1, corresponding
to an over 1,000 times removal. Host cell DNA concentrations
were below the detection limit of 78.13 pg mL-1 which is below
the maximum level allowed in a single human dose (shd)
(Table 2).
After IEX the Sabin PV was inactivated during a 13-day
incubation period with formaldehyde. PV was inactivated
rapidly, i.e. within 4 days, as shown in Figure 3E. After 6 to 8
days an intermediate filtration step was carried out to remove
possible aggregates and ensure full inactivation. After
inactivation a large variation in D-antigen recovery was
observed, especially for Sabin PV type 3. Overall recoveries
ranged from acceptable (in conventional IPV manufacturing on
average approximately 40% for all three sub-types [13,37]), for
Sabin PV type 1 (at 40%) to very low, with respect to future
Next Generation IPV Manufacturing
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cost competitive processing, for PV type 2 (at Table 3). The
obtained monovalent bulks met all release criteria and were
stored at 4°C prior to mixing for formulation.
Formulation.  Monovalent bulks were mixed to a trivalent
bulk (Sabin PV type 1-2-3) in a ratio of 60-96-192 DU mL-1 prior
to formulation to a final bulk. Different final bulks were
prepared. Plain sIPV was prepared in different final
concentrations of D-antigen to be able to test low (5-8-16 DU
shd-1) middle (10-16-32 DU shd-1) and high (20-32-64 DU shd-1)
dosages in (non-)clinical studies. Aluminium (Al(OH)3)
adjuvanted vaccine was mixed at 2-fold lower D-antigen values
being: low (2.5-4-8 DU shd-1), middle (5-8-16 DU shd-1) and
high (10-16-32 DU shd-1). Vaccine was filled in vials as 0.5 mL
per single human dose.
Pre-clinical studies
The immunogenicities in terms of the capacity to induce virus
neutralizing antibody titers (VNT) against the wild-type PVs (PV
Type 1 Mahoney, PV Type 2 MEF-1 and PV Type 3 Saukett) of
the six differently formulated vaccines were determined in rats
Figure 2.  Cell and virus culture.  Panel A shows the average Vero cell growth curve (n=12; error bars represent SD) in 350-L
bioreactors. Photographs are light microscopy images (size bar 200 µm). Panel B shows the average (of the three subtypes) Vero
cell death during virus culture determined microscopically (n=12; error bars represent SD). Photographs show corresponding
images. Panel C shows average virus titers for Sabin PV type 1, 2 and 3 (n=4; error bars represent SD). Panel D shows average D-
antigen concentrations after virus culture for Sabin PV type 1, 2 and 3 (n=4; error bars represent SD).
doi: 10.1371/journal.pone.0083374.g002
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[31,32]. High VNT against wild-type viruses were observed for
all prepared formulations (i.e. 0.5 mL of high, middle and low
DU). The maximum VNT for PV type 1 was lower than for PV
type 2 and 3 (Figure 4A-C). For all types, the VNT increased
with the dose and the addition of aluminium as adjuvant had a
positive effect. For PV type 2 this effect was larger than for PV
type 1 and PV type 3. Compared to conventional IPV,
immunization of rats with sIPV resulted in comparable wild-type
VNTs for PV type 1 and 3. Lower VNTs were found for PV type
2 when immunized with sIPV, however the levels of antibodies
raised are very high (>8 log2) (Figure 4D-F). These data
suggest that sIPV may be able to raise sufficient protective
antibodies against all PV sub-types in humans, where the
threshold for protection is 3 log2 [38] and thereby would be non-
inferior to conventional IPV.
Stability of the clinical lots over a period of 24 months was
assessed based on immunogenicity in rats, D-antigen
concentration, amount of free D-antigen (in case of adjuvanted
vaccine) and more general parameters like sterility,
appearance and pH. Vaccine stability with respect to
immunogenicity in rats is illustrated in Figure 5A-D. Based on
the regression line slopes (derived from Figure 5A) and their
95% confidence intervals (Figure 5B) it was concluded that all
formulated clinical lots were stable with respect to
immunogenicity in rats (null hypothesis slope=0; α=0.05; result
p>0.05).
In a similar way, the stability of the D-antigen content in the
formulated clinical lots was reviewed. Slopes and their 95%
confidence intervals of the regression lines (as illustrated in
Figure 5C) were calculated. The measurement of D-antigen in
aluminium adjuvanted formulations was difficult as the D-
antigen needed to be desorbed from the aluminium prior to
performing the D-antigen ELISA. This hurdle is illustrated by
the larger confidence intervals found for the regression lines for
D-antigen stability for the adjuvanted vaccines (Figure 5D). As
a result no conclusions with respect to D-antigen stability could
be drawn for the adjuvanted vaccine. Stability regarding the D-
antigen content of the non-adjuvanted (plain) vaccine was good
(null hypothesis slope =0; α=0.05; result p>0.05).
A repeated dose and local tolerance toxicity study in rabbits
was conducted. Highest dose plain and adjuvanted sIPV were
compared to a placebo and conventional licensed IPV. Some
enlargement in local lymph nodes was found in all vaccine
treated groups. Generally, minimal to mild inflammation was
observed microscopically at the injection sites of all groups and
could be attributed to the injection trauma. More intense
inflammation was shown in the adjuvanted sIPV group, which
was, in contrast to the other groups, not diminished after the
two week recovery period. This was solely attributed to the
apparent persistence of the adjuvant. A longer recovery period
should have been chosen. The changes at the injection sites
as well as the changes noted in the local lymph nodes are
common findings in intramuscular vaccine studies meaning that
the vaccines are safe to use in clinical trials.
Discussion
The polio eradication program strives to a switch from OPV
to sIPV and currently at least one dose of IPV is recommended
[39]. In view of the relatively short timelines in the polio
eradication program it was chosen to prepare a sIPV with
limited process development time prior to production of clinical
lots. Based on the existing large scale IPV manufacturing
process development of sIPV was achieved. Main operating
differences were related to the observed precipitate during
inactivation, intrinsic virus properties resulting in adjustments in
tests (i.e. aluminium desorption prior to D-antigen
quantification) and limits required with respect to biosafety (i.e.
virus culture temperature). The final product met quality criteria
and could be released for testing in the clinical phase I/IIa
studies in adults and infants to show safety and proof of
principle.
Although a sIPV with required immunogenicity and purity
could be produced, the purification yields with respect to Sabin
PV type 2 were very low. These low levels will not result in a
cost competitive IPV product. However, in light of the polio
eradication program, and to pursue the fast implementation of
worldwide sIPV manufacturing, sIPV production was continued
despite the low type 2 yields. In this way it could be illustrated
whether such a product would be comparable or better for polio
vaccination compared to the conventional IPV.
The next step in the project is to transfer the manufacturing
knowledge to current vaccine manufacturers in low- and middle
income countries to replace the OPV production with sIPV
Table 3. Product recovery during processing of two batches for each serotype.
Virus subtype Harvest Clarification Concentration SEC2 IEX3 Inactivation Overall1
Sabin PV type 1 100% 86% 82% 62% 90% 84% 38%
 100% 89% 73% 67% 107% 85% 41%
Sabin PV type 2 100% 92% 77% 69% 20% 50% <15%
 100% 96% 54% 51% 35% 64% <15%
Sabin PV type 3 100% 91% 75% 75% 87% 36% 18%
 100% 88% 70% 83% 114% 72% 24%
Losses due to sampling were not considered for recovery calculations of individual unit operations. The overall product recovery includes losses due to sampling for in-
process and release tests as well as sampling for research purposes.
1 The overall DSP yield was calculated by dividing the amount of D-antigen units of the monovalent bulk by the amount of D-antigen units from the harvest. 2 Size Exclusion
Chromatography 3 Ion Exchange Chromatography
doi: 10.1371/journal.pone.0083374.t003
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Figure 3.  Purification of Sabin PV.  Panel A depicts a SEC chromatogram of Sabin PV type 1. The 1st peak contained mostly
large cell components; the 2nd peak contained the majority of PV, following peaks consist of smaller components. Panel B shows a
SDS-PAGE (4-20% gel); lanes represent (from left to right) the marker, the concentrated product, followed by the 1st and 2nd fraction
of SEC and finally the IEX purified PV. Panel C shows chromatograms of Sabin PV type 1 (left) and Sabin PV type 2 (right) IEX
purification. Panel D shows host cell protein (open) and DNA (solid) impurities. Panel E depicts the inactivation of PV, the gray area
indicates the lower detection limit. In chromatograms A and C, the dotted and solid lines represent absorbance at respectively
254nm and 280nm. Gray dotted lines indicate peak fractioning.
doi: 10.1371/journal.pone.0083374.g003
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production [3]. The presented manufacturing process is being
optimized in parallel with technology transfer. As product
registration for market authorization at local authorities will
require local clinical studies, necessary process optimizations
for an economically feasible product can be implemented prior
to this stage.
Worldwide efforts in the development of sIPV have recently
resulted in market authorization for two vaccines containing
sIPV in Japan [40]. Further, the Institute of Medical Biology,
Figure 4.  Rat immunogenicity (VNT against wild-type viruses).  Panel A, B and C: VNT (log2 titer) to immunization with plain
sIPV (blue) and adjuvanted sIPV (red) for PV type 1, 2 and 3 respectively; Panel D, E and F: VNT of plain sIPV 20/32/64 (light blue),
10/16/32 (red), 5/8/16 (green) and plain IPV 40/8/32 (dark blue) for PV type 1, 2 and 3 respectively. Error bars in panel A-F depict
standard deviation of the median (n=10 rats).
doi: 10.1371/journal.pone.0083374.g004
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Chinese Academy of Medical Sciences (Kunming, China) [41]
is currently performing clinical phase III studies [42]. This
parallel development of sIPV allows a solid base for future IPV
availability and minimization of risks with respect to biosafety
during manufacturing.
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